Moyamoya Disease
Conditions
Keywords
Cognitive Impairment, Moyamoya Disease
Brief summary
The purpose of this study is to comprehensively evaluate the risk factors for cognitive decline in patients with moyamoya disease, identify imaging target areas associated with cognitive damage in the brain, and explore the changes in brain structure and functional networks resulting from cerebral revascularization, as well as their relationship with cognitive improvement.
Detailed description
Moyamoya disease (MMD) is a chronic occlusive-stenosis cerebrovascular disease that characterized by the stenosis of internal carotid artery termination and the formation of net-like vessel. It is a multifactorial disease caused by genetic, inflammatory, immunological and other environmental factors. The specific pathogenesis of MMD is still unclear. The treatment modalities of revascularization and conservative management have been used in patients with MMD. Due to the long-term low perfusion state of brain tissue, most patients with MMD experience varying degrees of cognitive dysfunction, although the underlying mechanisms remain unclear. We will employ a combination of 256-lead high-density electroencephalography, multimodal magnetic resonance imaging, and biological samples to conduct a comprehensive evaluation of the risk factors associated with cognitive decline in patients with MMD. Our objectives include identifying target imaging areas indicative of cognitive damage in the brain and exploring the structural and functional changes in the cerebral network resulting from revascularization, as well as their relationship with cognitive improvement.
Interventions
PROCEDURERevascularization
Revascularization
Sponsors
Beijing Tiantan Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* The admission cerebral angiography (DSA) examination fulfills the diagnostic criteria for moyamoya disease. * Please sign the informed consent form. * Participants must be between 18 and 60 years of age.
Exclusion criteria
* Patients with concurrent atherosclerosis, autoimmune diseases, meningitis, brain tumors, Down syndrome, craniocerebral trauma, prior radioactive head irradiation, or hyperthyroidism, which may result in secondary cerebrovascular lesions leading to symptoms associated with smoke syndrome. * Individuals younger than 18 years or older than 60 years. * Those with contraindications for magnetic resonance imaging. * Patients who are unable to complete cognitive brain assessments
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in composite score of neurocognitive function at 6 months after treatment. | 6 months during follow-up | The composite score of neurocognitive function, including Weschsler Adult Intelligence Scale-4th Edition (WAIS-IV), MATRICS Consensus Cognitive Battery (MCCB), Montreal Cognitive Assessment (MoCA), Auditory Verbal Learning Test (AVLT), Rey-Osterrieth complex figure (ROCF), Trail Making Test (TMT), Stroop test, Verbal Fluency Test (VFT), and Boston Naming Test (BNT) will be collected before and 6 months after treatment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Structural Connectivity Strength assessed by multimodal MRI at 6, 12, and 24 months after treatment. | 6, 12 and 24 months during follow-up | — |
| Changes in Network Density assessed by multimodal MRI at 6, 12, and 24 months after treatment. | 6, 12 and 24 months during follow-up | — |
| Changes in composite score of neurocognitive function at 12 and 24 months after treatment. | 12 and 24 months during follow-up | The composite score of neurocognitive function, including Weschsler Adult Intelligence Scale-4th Edition (WAIS-IV), MATRICS Consensus Cognitive Battery (MCCB), Montreal Cognitive Assessment (MoCA), Auditory Verbal Learning Test (AVLT), Rey-Osterrieth complex figure (ROCF), Trail Making Test (TMT), Stroop test, Verbal Fluency Test (VFT), and Boston Naming Test (BNT) will be collected before and 12 and 24 months after treatment. |
| Rate of participants experiencing cerebrovascular events (TIA, infarction and hemorrhage) within 6, 12 and 24 months after treatment. | 6, 12 and 24 months during follow-up | — |
| Changes in neurological function assessed by modified Rankin scale (mRS) at 6, 12, and 24 months following treatment. | 6, 12 and 24 months during follow-up | — |
| Changes in neurological function assessed by National Institute of Health stroke scale (NIHSS) at 6, 12, and 24 months following treatment. | 6, 12 and 24 months during follow-up | — |
| Changes in Clustering Coefficient assessed by multimodal MRI at 6, 12, and 24 months after treatment. | 6, 12 and 24 months during follow-up | — |
| Hemodynamic changes at the terminal segment of internal carotid artery assessed by computational fluid dynamics (CFD) at 6, 12, and 24 months after treatment. | 6, 12 and 24 months during follow-up | — |
| Morphological changes at the terminal segment of internal carotid artery and middle cerebral artery wall assessed by high-resolution vessel wall imaging at 6, 12, and 24 months after treatment. | 6, 12 and 24 months during follow-up | — |
| Changes in Power Spectral Density (PSD) assessed by electroencephalography (EEG) at 6, 12, and 24 months after treatment will be measured. | 6, 12 and 24 months during follow-up | — |
| Changes in Phase Locking Value (PLV) assessed by electroencephalogram (EEG) at 6, 12, and 24 months after treatment will be measured. | 6, 12 and 24 months during follow-up | — |
| Changes in Phase-Lag Index (PLI) assessed by electroencephalogram (EEG) at 6, 12, and 24 months after treatment will be measured. | 6, 12 and 24 months during follow-up | — |
| Changes in Degree Centrality assessed by multimodal MRI at 6, 12, and 24 months after treatment. | 6, 12 and 24 months during follow-up | — |
| Changes in cerebral blood perfusion assessed by arterial spin labeling (ASL) at 6, 12, and 24 months after treatment. | 6, 12 and 24 months during follow-up | — |
Countries
China
Contacts
Primary ContactQian Zhang, MD
Backup ContactChaofan Zeng, MD
Outcome results
None listed